Elacestrant as second-line therapy for ESR1-mutated, endocrine-sensitive disease

Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on results from an analysis of data from the EMERALD study that were reported at the San Antonio Breast Cancer Symposium (SABCS) 2022. This analysis identified duration of prior CDK4/6 inhibitor therapy as a potential surrogate marker for endocrine sensitivity, and discusses how these findings could help guide patient selection for elacestrant.

EP: 1.Overview of phase 3 EMERALD study of elacestrant for ER+, HER2- MBC

EP: 2.Episode 2: Incidence of ESR1 mutations and best practices for testing

EP: 3.Co-occurrence of ESR1 mutations with other alterations

Now Viewing

EP: 4.Elacestrant as second-line therapy for ESR1-mutated, endocrine-sensitive disease

EP: 5.EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease

EP: 6.Elacestrant: Clinical Pearls for Adverse Effect Management

EP: 7.Emerging data on oral selective estrogen receptor degraders

Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.

Recent Videos